All Blogs
Jan 28, 2026
Advances in Varicose Vein Treatment Devices: Technologies Shaping Modern Venous Care
Varicose veins, enlarged, tortuous veins most commonly occurring in the lower extremities, impact millions worldwide, causing discomfort, cosmetic concerns, and, in severe cases, complications such as venous insufficiency or ulcers. While traditional varicose vein treatments such as compression stockings and surgic...
Read More...
Jan 27, 2026
Sanofi Strengthens Amlitelimab’s Position in Atopic Dermatitis; Corcept Announces Statistically Significant Overall Survival Benefit in Phase 3 ROSELLA Study; CORXEL Raises $287M Series D1 for Cardiometabolic Pipeline Expansion; IntraBio’s Levacetylleucine Demonstrates Positive Results in Pivotal Ataxia-Telangiectasia Trial; Otsuka Secures FDA Acceptance and Priority Review for Centanafadine in ADHD
Sanofi’s Amlitelimab Demonstrates Promise in Atopic Dermatitis Following the positive findings from the COAST 1 trial (NCT06130566) reported in September 2025, two additional global Phase 3 studies, SHORE (NCT06224348) and COAST 2 (NCT06181435), have further strengthened the clinical evidence supporting amliteli...
Read More...
Jan 26, 2026
ASPAVELI Fuels Sobi’s Growth Strategy in Europe for C3G and IC-MPGN
Summary Sobi has received European Commission approval for ASPAVELI (pegcetacoplan) to treat C3G and primary IC-MPGN, two rare, progressive kidney diseases. The approval follows a positive CHMP opinion (December 2025) and marks the first approved treatment for primary IC-MPGN and the first for both C3G...
Read More...
Jan 23, 2026
JPM 2026 Recap: Who’s Winning, Who’s Catching Up, and Who’s at Risk?
The 44th Annual J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco, revealed a pharmaceutical sector at an inflection point. With major blockbusters facing patent expirations, industry leaders such as Eli Lilly, Novo Nordisk, Bristol Myers Squibb, AbbVie, Bayer, Pfizer, Novartis, Roche, M...
Read More...
Jan 22, 2026
Sonomotion Secures FDA Clearance for Break Wave™ Lithotripsy System; Aidoc Earns FDA Clearance for Comprehensive AI Foundation Model in Healthcare; BD and Ypsomed Deepen Partnership to Serve Expanding Biologics Market; Omnia Medical Launches FDA-Approved PsiF DNA™ System to Market; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; NEURO PMR Data Validates Hyperfine’s Diagnostic Precision and Patient-Centered Care
Sonomotion Announced FDA Clearance for its Break Wave™ Lithotripsy Device for Treatment of Kidney Stones On January 21, 2026, SonoMotion, a venture-backed medical device company focused on developing non-invasive solutions for kidney stone treatment, announced that it had received U.S. Food and Drug Admini...
Read More...
Jan 21, 2026
The Evolution of Vascular Access Devices in Modern Medicine
In the intricate world of modern clinical practice, the ability to safely and reliably access a patient's circulatory system is perhaps the most fundamental requirement of acute and chronic care. Vascular Access Devices (VADs), ranging from simple peripheral catheters to complex implanted ports, serve as the "highw...
Read More...
Jan 20, 2026
Nxera Pharma Confirms Positive Phase 3 Findings for Daridorexant in South Korea; AstraZeneca Strengthens Oncology Pipeline in China With GPC3 Armored CAR-T Rights From AbelZeta; AbbVie Shares Topline Findings from Phase 3 EPCORE DLBCL-1 Study of Epcoritamab; ImmunityBio Achieves Prolonged Complete Response Using Chemotherapy-Free CD19 CAR-NK Platform; Sobi Wins EU Approval for ASPAVELI to Treat C3G and Primary IC-MPGN
Nxera Pharma Reports Positive Phase 3 Trial Results for Daridorexant in South Korea Nxera Pharma announced top-line results from its pivotal Phase 3 clinical trial of daridorexant in South Korea, showing that the study successfully met both primary and secondary endpoints in adult and elderly patients with insom...
Read More...
Jan 19, 2026
Chronic Venous Insufficiency Treatment: Bridging Unmet Needs with Minimally Invasive and Regenerative Solutions
Summary In the seven major markets (7MM: US, EU4, UK, Japan), diagnosed cases of CVI reached ~17 million in 2024. Prevalence is projected to grow at a 1.4% CAGR, reaching ~20 million by 2034, driven by aging populations, obesity, sedentary lifestyles, and improved diagnostics. Endovenous laser ablation...
Read More...
Jan 16, 2026
Cancer Cachexia Drug Landscape Heats Up with Multiple Assets Advancing—7 Therapies to Watch Out
Summary Cancer cachexia is a severe, multifactorial wasting syndrome affecting most advanced cancer patients, with no approved therapies in the US or Europe and only ADLUMIZ approved in Japan, underscoring a major unmet need. Despite the historical treatment gap, the cancer cachexia pipeline is now rapidly e...
Read More...
Jan 15, 2026
Medtronic Diabetes Secures FDA Clearance for MiniMed Go™ Smart MDI Platform; Neurolief Achieves FDA PMA Approval for Novel At-Home Brain Stimulation Therapy for Depression; Haemonetics Completes Acquisition of Vivasure Medical Limited; Boston Scientific Enters Agreement to Acquire Valencia Technologies; Butterfly Medical Completes Pivotal Trial for Minimally Invasive BPH Therapy; TYBR Health Announces First U.S. Clinical Use of the B3 GEL™ System
Medtronic Diabetes Announced FDA Clearance for MiniMed Go™ Smart MDI System Featuring Instinct Sensor Made by Abbott On January 12, 2026, Medtronic, a global leader in healthcare technology, announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MiniMed Go™ app. The MiniM...
Read More...